Download PDF
Thromb Haemost 1999; 82(S 01): 124-126
DOI: 10.1055/s-0037-1615569
Commentaries
Schattauer GmbH

Oral Anticoagulation after a First Episode of Venous Thromboembolism: How Long? How Strong?

H. H. Watzke
1   From the Department of Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

A number of studies have been published in the last years which shed light on the optimal intensity and the optimal duration of oral anticoagulation in patients with venous thrombosis.

Based on these studies it is now generally recommended to treat patients with venous thromboembolism at an INR ranging from 2.0 to 3.0. The optimal duration of anticoagulation mainly depends on the nature of the thrombotic event. In patients with a temporary prothrombotic risk factor such as surgery, immobilization or trauma a relatively short duration of oral anticoagulation (3-6 months) is generally recommended. Patients with idiopathic venous thromboembolism require a considerably longer duration of anticoagulation (6 months at least).

Key words

Oral anticoagulation - venous thromboembolism
 

  • References

  • 1 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
    CrossrefPubMedGoogle Scholar
  • 2 Hull RD, Delmore TJ, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 2301: 855-8.
    PubMedGoogle Scholar
  • 3 Lagerstedt CI, Olsson CG, Fagher BO, Oquist BW, Albrechtson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2 (8454) 515-8.
    PubMedGoogle Scholar
  • 4 Lehman J. Hypoprothrombinaemia produced by methylene-bis-hydroxy-coumarin, its use in thrombosis. Lancet 1942; 120: 1009-15.
    PubMedGoogle Scholar
  • 5 Landefeld CS, Beyth RJ. Anticoagulant related bleeding - clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28.
    CrossrefPubMedGoogle Scholar
  • 6 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
    CrossrefPubMedGoogle Scholar
  • 7 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
    CrossrefPubMedGoogle Scholar
  • 8 Hirsh J, Fuster V. Guide to anticoagulation therapy part 2: oral anticoagulants. Circulation 1994; 89: 1469-78.
    CrossrefPubMedGoogle Scholar
  • 9 Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114: 561S-7S.
    CrossrefPubMedGoogle Scholar
  • 10 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
    CrossrefPubMedGoogle Scholar
  • 11 Schulman S, Rhedin AS, Lindmaker P. et al. The Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after the a first episode of venous thromboembolism. N Engl J Med. 1995 332. 1661. 5.
    PubMedGoogle Scholar
  • 12 Kakkar Vv, Howe CT, Nicolaides AN. Deep vein thrombosis of the legs: is there a high risk group?. Am J Surg 1970; 120: 527-30.
    CrossrefPubMedGoogle Scholar
  • 13 Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis?. Ann Intern Med 1981; 94: 439-44.
    CrossrefPubMedGoogle Scholar
  • 14 Lagerstedt CI, Olsson C-G, Fagher BO. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-8.
    PubMedGoogle Scholar
  • 15 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Schulman S, Granqvist S, Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
    CrossrefPubMedGoogle Scholar
  • 17 Schulman S, Svenungsson E, Granqvist S. and The Duration of Anticoagulation Study Group Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-8.
    CrossrefPubMedGoogle Scholar
  • 18 Ridker P, Miletich J, Stampfer M, Goldhaber S, Lindpaintner K, Hennekens C. Factor V Leiden and the risk of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
    CrossrefPubMedGoogle Scholar
  • 19 Simioni P, Parndoni P, Lensing A. et al. The risk of recurrent venous thromboembolism in patients with an Arg506 to Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
    CrossrefPubMedGoogle Scholar
  • 20 Baglin C, Brown K, Luddington R, Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. Brit J Haematol 1998; 100: 764-8.
    CrossrefPubMedGoogle Scholar
  • 21 Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczk C, Schneider B. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Heamost 1997; 4: 624-8.
    PubMedGoogle Scholar
  • 22 Lindmarker P, Schulman S, Sten-Lindner M, Wiman B, Egberg N, Johnsson H. The risk of recurrent thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684-9.
    PubMedGoogle Scholar
  • 23 Sarasin PS, Bounamaeux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. Brit J Haematol 1998; 316: 95-9.
    PubMedGoogle Scholar
  • 24 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
    PubMedGoogle Scholar
  • 25 Lane DA, Manucci PM, Bauer KA. et al. Inherited thrombophilia: Part 1. Thromb Haemost. 1996 76. 651.
    PubMedGoogle Scholar
  • 26 Lane DA, Manucci PM, Bauer KA. et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 823-34.
    PubMedGoogle Scholar
  • 27 Dahlback B. inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
    PubMedGoogle Scholar
  • 28 Den Heijer M, Kostner T, Blom JH. et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
    CrossrefPubMedGoogle Scholar
  • 29 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78 (1) 297-301.
    Article in Thieme ConnectPubMedGoogle Scholar